Seven members of the Center for Medical Device Evaluation presented at the 2026 Transcatheter Cardiovascular Therapeutics (TCT) symposium in San Francisco, CA this past weekend.
🔵 Dr. PK Gaba presented on utilization and outcomes of percutaneous coronary interventions (PCI) using intravascular lithotripsy (IVL), centering results from the ACC NCDR CathPCI Registry.
⚪ Dr. Bobby Yeh presented on multiple topics, including the investigational device exemption (IDE) study for Shockwave's Javelin catheter, statistical considerations for trial design, and restoring vessel compliance for long-term PCI success. He also served as a discussant and moderator on several panels.
🔵 Dr. Eric Secemsky introduced the primary results of Abbott's TECTONIC CAD IVL IDE study, for which he is Global PI, as a late-breaker and gave a presentation on takeaways from the SirPAD (Sirolimus-coated balloon for PAD) trial. He also served as a discussant and moderator on several panels.
⚪ Dr. Christina Lalani debuted the one-year outcomes of the AGENT Drug-Coated Balloon in clinical practice and gave presentations on transportability of the DanGER Shock trial and adoption of drug-coated balloon therapy, respectively. She also served as a discussant on several panels.
🔵 Dr. Matthew Herzig presented two studies evaluating radiation exposure reduction to cath lab operators with use of Rampart's radiation protection systems.
⚪ Dr. Joseph Kim gave two presentations, one on the impact of timing of coronary angiography on in-hospital outcomes in non-ST elevation Acute Coronary Syndrome and the other on race-based differences in timing and treatment escalation for acute pulmonary embolism.
🔵 Dr. Hyeok-Hee Lee presented his research on proteomic signatures of response to renal denervation (the PRECISE-RDN pilot study).
Congrats to all!
Â
Â
